• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

A Comparative High-Throughput Screening Protocol to Identify Entry Inhibitors of Enveloped Viruses

tetano

Editor, Senior Moderator
J Biomol Screen. 2013 Jul 2. [Epub ahead of print]
A Comparative High-Throughput Screening Protocol to Identify Entry Inhibitors of Enveloped Viruses.
Wang J, Cheng H, Ratia K, Varhegyi E, Hendrickson WG, Li J, Rong L.
Source

1Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, IL, USA.
Abstract

Emerging and reemerging human viral pathogens pose great public health concerns since therapeutics against these viruses are limited. Thus, there is an urgent need to develop novel drugs that can block infection of either a specific virus or a number of viruses. Viral entry is thought to be an ideal target for potential therapeutic prevention. One of the challenges of developing antivirals is that most of these viruses are highly pathogenic and therefore require high biosafety-level containment. In this study, we have adopted a comparative high-throughput screening protocol to identify entry inhibitors for three enveloped viruses (Marburg virus, influenza virus H5N1, and Lassa virus) using a human immunodeficiency virus-based pseudotyping platform. We demonstrate the utility of this approach by screening a small compound library and identifying putative entry inhibitors for these viruses. One major advantage of this protocol is to reduce the number of false positives in hit selection, and we believe that the protocol is useful for inhibitor screening for many enveloped viruses.
KEYWORDS:

antiviral drugs, cell-based assays, comparative HTS, high-throughput screening, phenotypic drug discovery

PMID:
23821643
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23821643
 
Back
Top Bottom